Skip to main content
STARPHARMA HOLDINGS LIMITED logo

STARPHARMA HOLDINGS LIMITED — Investor Relations & Filings

Ticker · SPL ISIN · AU000000SPL0 LEI · 254900WRGE3OUSWGMB55 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,316 across all filing types
Latest filing 2023-11-09 Board/Management Inform…
Country AU Australia
Listing ASX SPL

About STARPHARMA HOLDINGS LIMITED

https://starpharma.com/

Starpharma Holdings Limited is a biopharmaceutical company focused on the development of dendrimer technology for pharmaceutical and life science applications. The company utilizes its proprietary DEP® (Dendrimer Enhanced Product) delivery platform to improve the performance of existing drugs by enhancing solubility, reducing toxicity, and providing targeted delivery. Its clinical-stage internal pipeline includes DEP® docetaxel, DEP® cabazitaxel, and DEP® irinotecan, primarily targeting oncology. Starpharma also markets VivaGel® BV, a non-antibiotic treatment and prevention for bacterial vaginosis, and VIRALEZE™, an antiviral nasal spray containing astodrimer sodium. The company collaborates with global pharmaceutical firms to apply its dendrimer technology to various therapeutic areas, including antibody-drug conjugates and radiopharmaceuticals.

Recent filings

Filing Released Lang Actions
Starpharma announces new CEO, Ms Cheryl Maley 4 pages 280.9KB
Board/Management Information Classification · 100% confidence The document is a detailed announcement about the appointment of a new CEO and Managing Director at Starpharma, including biographical information, comments from the Chair and the incoming CEO, and a summary of the key terms of the executive employment agreement. It focuses on management changes and executive compensation terms. There is no financial data, earnings information, or regulatory filing references. The content fits the category of announcements related to changes in the company's board or senior management rather than financial reports or other filings.
2023-11-09 English
Application for quotation of securities - SPL 7 pages 29.6KB
Share Issue/Capital Change Classification · 95% confidence The document is an application for quotation of securities issued under an employee incentive scheme by Starpharma Holdings Limited. It details the number and type of securities to be quoted, issue dates, and compliance with ASX Listing Rules. There is no financial performance data, management discussion, or report content. The document is a regulatory announcement related to capital market activities, specifically the quotation of securities, which aligns with announcements about share issues or capital changes. Therefore, the document fits best under the category of Share Issue/Capital Change (SHA). The document length and content confirm it is not a brief notice but a full announcement of a capital market event.
2023-11-09 English
Notification regarding unquoted securities - SPL 7 pages 29.7KB
Share Issue/Capital Change Classification · 100% confidence The document is a notification regarding the issue of unquoted equity securities, specifically performance rights issued under an employee incentive scheme. It details the number of securities issued, the date of issue, and mentions key management personnel recipients. The document is an announcement of a securities issuance event rather than a financial report or detailed analysis. It fits the category of announcements related to share issues or capital changes. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length and content confirm it is not a brief report publication announcement or a regulatory filing fallback.
2023-11-05 English
Quarterly Activities/Appendix 4C Cash Flow Report 8 pages 775.7KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Activities Report & Appendix 4C' and covers the period ended 30 September 2023 (Q1 FY24). It contains detailed operational updates, clinical trial progress, financial cash position, and other business activities for the quarter. The presence of substantive financial data such as cash balances, net cash inflows, and R&D tax incentive refunds, along with detailed discussion of clinical trial results and business progress, indicates this is a comprehensive quarterly report rather than a brief announcement or presentation. The document is about a period shorter than a full fiscal year and includes actual financial and operational data, fitting the definition of an Interim / Quarterly Report (IR). Q1 2024
2023-10-30 English
Notice of Annual General Meeting/Proxy Form 24 pages 15.0MB
AGM Information Classification · 100% confidence The document is titled 'Notice of Annual General Meeting 2023' and contains detailed information about the upcoming AGM of Starpharma Holdings Limited, including the date, time, location, participation methods (in person and online), items of business to be voted on, board renewals, voting instructions, proxy details, and voting exclusions. It includes an invitation from the Chair, details on how to attend and participate, and the formal Notice of Meeting with resolutions to be considered. There is no actual financial data or results presented, nor is this a transcript or report of the meeting itself. The document is clearly the official notice and invitation to the AGM, which fits the definition of AGM Information (AGM-R). The length and detail confirm it is not a brief announcement or proxy solicitation but the full AGM notice and related information.
2023-10-26 English
SPL to present DEP radiotheranostics at Wilsons Conference 14 pages 2.1MB
Investor Presentation Classification · 95% confidence The document is a detailed announcement and presentation related to Starpharma's participation in the Wilsons Drug and Device Conference. It includes an overview of the company, its clinical trial results, product pipeline, partnerships, and financial position. The content is structured as a presentation for investors and market participants, focusing on the company's technology, clinical programs, and strategic positioning. There are no financial statements, quarterly or annual results, or regulatory filings such as 10-K or interim reports. The document is not an earnings release, audit report, or legal proceeding update. It is clearly a presentation given at a conference aimed at investors, which matches the definition of an Investor Presentation (IP). The length (15,000 characters) and detailed content support this classification rather than a brief announcement or a report publication announcement.
2023-10-25 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.